FALLS CHURCH VA USA — MEDICAL INDUSTRY E-MAIL NEWS SERVICE(TM) — JULY 19 2005 — The FDA Symposium, to be held Aug 24-26 2005, will cover regulatory and compliance topics, plus provide practical advice on managing risks for FDA-regulated companies.
This 3-day event will focus on potential changes to drug labeling, priorities of the next FDA Director of the Office of Drug Safety, ways to keep your products off the FDA’s new Drug Watch website, and challenges of Patient Information Sheets and Healthcare Alerts.
VIEW THE FULL CONFERENCE AGENDA:
More than 30 of the drug industry’s top regulators, decision-makers and opinion leaders are attending, including:
— John M. Taylor III, FDA’s former Associate Commissioner for Regulatory Affairs, kicks things off with a keynote speech updating attendees on the FDA’s latest regulatory and compliance agenda.
— 2 former FDA chief counsels — Peter Barton Hutt Esq and Daniel E. Troy Esq — plus former FDA associate chief counsel Mark S. Brown Esq
— Top executives of Baxter Healthcare, Allergan, Biogen Idec, Wyeth, Genzyme, Sanofi-Aventis, Purdue Pharma, Kendle and Tap Pharmaceuticals
— Powerful lobbyists and consultants from EduQuest, AAC Consulting, Louis A. Morris Associates, Quantic Group, APCO Worldwide and Weinberg Group
The FDA Symposium takes place on the Harvard University campus, possibly the most intellectually stimulating conference venue in the US. Add on a few days of personal time to catch New England’s glorious last days of summer and gird for the challenging year ahead.
WHEN & WHERE:
THE FDA REGULATORY & COMPLIANCE SYMPOSIUM
Managing Risks — From Pipeline to Patient
Aug 24-26 2005
On the Harvard University campus, Cambridge MA
Register by July 22 and receive $200 off your conference registration.
The Symposium is sponsored by FDAnews, Harvard Health Policy Review and Health Affairs.
FOR FURTHER INFORMATION, PLEASE CONTACT
300 N Washington St Ste 200
Falls Church VA USA 22046